High-dose-rate brachytherapy monotherapy achieved durable prostate cancer control
High-dose-rate brachytherapy monotherapy achieved 86% biochemical control at median 13-year follow-up in localized prostate cancer.
Tag
prostate
Same-day hyaluronic acid spacer reduced rectal dose in prostate brachytherapy
Same-day hyaluronic acid rectal spacer placement reduced rectal dose while preserving ultrasound-based prostate brachytherapy planning.
Magnetic resonance-only simulation supported prostate magnetic resonance-guided stereotactic body radiotherapy
Magnetic resonance-only prostate simulation achieved 96.80% local gamma agreement using synthetic computed tomography for dose calculation.
Rectal air did not compromise prostate online adaptive radiotherapy robustness
Rectal air or air-filled balloons did not cause clinically relevant dose increases when posterior tissue shifts stayed within 5 millimetres.
Daily adaptive prostate stereotactic body radiotherapy improved target coverage
Daily cone-beam computed tomography-based adaptation improved prostate stereotactic body radiotherapy target coverage, but organ-at-risk dose benefits were inconsistent.
Larger bladder geometry was linked to lower planned bladder dose in prostate radiotherapy
Larger bladder volume was strongly associated with lower planned bladder dose in a static five-fraction prostate radiotherapy analysis.
High lactate dehydrogenase-5 and low lymphocyte infiltration identified higher relapse risk after prostate radiotherapy
Combined high lactate dehydrogenase-5 expression and low tumor-infiltrating lymphocyte density independently identified higher biochemical relapse risk after prostate radiotherapy.
Severe late toxicity was generally uncommon after prostate radiotherapy in REQUITE
Across 1,760 patients, most grade 3 adverse events remained below 1.5%, although post-prostatectomy urinary incontinence reached 10.2% by eight years.
Knowledge-based prostate planning transfers across fractionation regimens with comparable plan quality
A conventional-fractionation model produced clinically acceptable moderately hypofractionated prostate plans, with comparable overall quality and slightly reduced target homogeneity.
Single-fraction prostate radiotherapy achieved 92.9% three-year biochemical relapse-free survival
A single 19-Gy fraction achieved 92.9% three-year biochemical relapse-free survival with limited grade 2 gastrointestinal and genitourinary toxicity.